Phost’in Therapeutics and Fondazione Gianni Bonadonna to present first clinical data on PhOx430, a First-In-Class GnT-V inhibitor, at @myesmo.bsky.social 2025. Press release fondazionebonadonna.org/wp-content/u...
#PhostInTherapeutics #FondazioneBonadonna #therapeuticinnovation #CancerResearch
0
0
0
0